CNS Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-5.66; its P/E ratio is -0.04; CNS Pharmaceuticals is scheduled to report earnings on May 13, 2024, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	-	-	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	$ -4.52M	$ -4.02M	$ 4.93M	$ -5.50M	$ -3.42M
EBITDA	$ -4.52M	$ -4.02M	$ 4.93M	$ -5.17M	$ -3.42M
Net Income Common Stockholders	$ -4.52M	$ -4.02M	$ 4.92M	$ -5.50M	$ -3.42M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 909.55K	$ 4.28M	$ 5.11M	$ 10.06M	$ 7.03M
Total Assets	$ 2.33M	$ 6.45M	$ 7.41M	$ 13.05M	$ 9.64M
Total Debt	$ 41.90K	$ 166.40K	$ 289.07K	$ 409.97K	$ 39.26K
Net Debt	$ -867.64K	$ -4.11M	$ -4.82M	$ -9.65M	$ -6.99M
Total Liabilities	$ 4.07M	$ 4.00M	$ 3.92M	$ 4.92M	$ 1.24M
Stockholders Equity	$ -1.74M	$ 2.45M	$ 3.49M	$ 8.13M	$ 8.39M
Cash Flow	-
Free Cash Flow	$ -3.38M	$ -3.40M	$ -4.82M	$ -2.31M	$ -1.81M
Operating Cash Flow	$ -3.38M	$ -3.40M	$ -4.82M	$ -2.31M	$ -1.81M
Investing Cash Flow	$ -1.74K	-	-	$ 1.00	$ -1.51K
Financing Cash Flow	$ 8.36K	$ 2.57M	$ -120.28K	$ 5.33M	$ -117.14K

Currency in USD

CNS Pharmaceuticals Earnings and Revenue History

Income Statement >

CNS Pharmaceuticals Debt to Assets

Balance Sheet >

CNS Pharmaceuticals Cash Flow

Cash Flow >

CNS Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing